Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on May 14, 2025

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different …

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed …

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

Live webcast followed by an interactive Q…

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary …

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven …

Progyny Appoints Two Renowned Women’s Health Experts to Medical Advisory Board

Progyny Appoints Two Renowned Women’s Health Experts to Medical Advisory Board

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the appointment of Morehouse School of Medicine’s Regional Dean for Seattle and Puget Sound’s Dr. …

Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors

Outset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of Directors

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of …

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical …

The Dwayne Andrews Glioblastoma Research Grant Awarded to Dr. Jeremy Brown, Dalhousie University

The Dwayne Andrews Glioblastoma Research Grant Awarded to Dr. Jeremy Brown, Dalhousie University

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to announce The Dwayne Andrews Glioblastoma Research Grant of $85,000 awarded to Dr. Jeremy Brown at Dalhousie University for his project, "Clinical Testing of a High-Resolution …

The American Kidney Fund’s ‘A Step Ahead of IgA Nephropathy’ Campaign Provides New Resources for Patients Living with IgA Nephropathy

The American Kidney Fund’s ‘A Step Ahead of IgA Nephropathy’ Campaign Provides New Resources for Patients Living with IgA Nephropathy

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Today, on IgA Nephropathy Awareness Day, the American Kidney Fund (AKF) proudly announces the creation of new educational resources for “A Step Ahead of IgA Nephropathy,” its newly updated educational …

Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.

Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.

BOWIE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Internationally acclaimed neurologist and epilepsy researcher Dr. Orrin Devinsky will be honored with the Lifetime Accelerator Award during the Epilepsy Therapies …

Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer

Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered …

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first …

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an …

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, …

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for …

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary …

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann …

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at recent congresses reinforces the potential …

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service